Eli Lilly is set to make an $18 million milestone payment to Hutchison MediPharma, majority owned by Hutchison China MediTech, or Chi-Med, in the second quarter of 2015 after a positive first proof-of-concept study result for fruquintinib, a candidate for treatment of patients with metastatic colorectal cancer in China.
When Eli Lilly bought Novartis Animal Health last year, it picked up a product that the FDA had in its crosshairs: Denagard (tiamulin hydrogen fumarate) plus CTC (chlortetracycline hydrochloride), a medicated feed product for pigs. The product is an antibiotic, and the FDA wants Lilly to stop marketing it for weight gain.
Which diabetes med is likely to be on top in 2020? According to FirstWord Pharma, that would be--surprise!--Lantus, albeit as a $5 billion shadow of its former self. Januvia should keep its hold on second prize with almost $4 billion, while Novo Nordisk's NovoRapid and Lilly's Humalog remain in the top 5 with $3.6 billion and $3.04 billion in sales.
Eli Lilly announced last week that it will be opening a drug delivery and device innovation center in Cambridge, MA, as it seeks to meet the needs of its pipeline, such as a suitable formulation for its osteoporosis candidate, and maintain its leadership position in diabetes, where delivery devices are key.
Eli Lilly has turned to Germany's BioNTech to form its latest collaboration on the cancer immunotherapy front, handing over $60 million--$30 million as a signing bonus and $30 million for equity--and promising up to $300 million in milestones for each new program that can go the distance.
Canada's Transition Therapeutics is expanding its relationship with Eli Lilly, promising up to $100 million in exchange for a muscle-boosting drug candidate.
Eli Lilly will open a new drug delivery and device innovation center in Cambridge, MA. Medical devices aren't a focus for the pharma now--but it noted that more than half of its current pipeline candidates are biologics that require injection. It expects to double its revenues from device-enabled products by 2020 and is looking to have a hand in that arena.
Eli Lilly is the latest multinational drugmaker looking to Cambridge, MA, to jump-start its innovation engine, blueprinting a new R&D outpost on the Charles River as biotech's hippest neighborhood gets more and more crowded.
It's the big numbers that tend to make headlines during earnings season: Overall sales, top-selling meds, and, of course, earnings per share. Some closely watched new drugs have a moment in the sun, too. But other launches? Barely a glimpse--if any at all. Here's a roundup of the launch stats that caught our eyes.
FiercePharmaAsia combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan to Southeast Asia.